-
1
-
-
33746833635
-
Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation-Executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation
-
Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol . 2006;48(4):854-906.
-
(2006)
J Am Coll Cardiol
, vol.48
, Issue.4
, pp. 854-906
-
-
Fuster, V.1
Ryden, L.E.2
Cannom, D.S.3
-
2
-
-
0035832261
-
Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study
-
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA . 2001;285(18):2370-2375.
-
(2001)
JAMA
, vol.285
, Issue.18
, pp. 2370-2375
-
-
Go, A.S.1
Hylek, E.M.2
Phillips, K.A.3
-
3
-
-
0028244264
-
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
-
Investigators AF. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med . 1994;154(13): 1449-1457.
-
(1994)
Arch Intern Med
, vol.154
, Issue.13
, pp. 1449-1457
-
-
Investigators, A.F.1
-
4
-
-
0037221236
-
Atrial fibrillation is associated with severe acute ischemic stroke
-
Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology . 2003;22(2): 118-123.
-
(2003)
Neuroepidemiology
, vol.22
, Issue.2
, pp. 118-123
-
-
Dulli, D.A.1
Stanko, H.2
Levine, R.L.3
-
5
-
-
0036844470
-
Prediction of length of stay of first-ever ischemic stroke
-
Chang KC, Tseng MC, Weng HH, Lin YH, Liou CW, Tan TY. Prediction of length of stay of first-ever ischemic stroke. Stroke . 2002;33(11):2670-2674.
-
(2002)
Stroke
, vol.33
, Issue.11
, pp. 2670-2674
-
-
Chang, K.C.1
Tseng, M.C.2
Weng, H.H.3
Lin, Y.H.4
Liou, C.W.5
Tan, T.Y.6
-
6
-
-
11044231366
-
An economic model of stroke in atrial fibrillation: The cost of suboptimal oral anticoagulation
-
discussion S458-S461
-
Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care . 2004;10(14) (suppl):S451-S458; discussion S458-S461.
-
(2004)
Am J Manag Care
, vol.10
, Issue.14 SUPPL.
-
-
Caro, J.J.1
-
7
-
-
0028343127
-
Risk factors for intracranial hemorrhage in outpatients taking warfarin
-
Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med . 1994;120(11): 897-902.
-
(1994)
Ann Intern Med
, vol.120
, Issue.11
, pp. 897-902
-
-
Hylek, E.M.1
Singer, D.E.2
-
8
-
-
4644230820
-
The pharmacology and management of the vitamin k antagonists: The seventh accp conference on antithrombotic and thrombolytic therapy
-
Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest . 2004;126(3)(suppl):204S-233S.
-
(2004)
Chest
, vol.126
, Issue.3 SUPPL.
-
-
Ansell, J.1
Hirsh, J.2
Poller, L.3
Bussey, H.4
Jacobson, A.5
Hylek, E.6
-
9
-
-
0037738891
-
Practical tips for warfarin dosing and monitoring
-
Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med . 2003;70(4):361-371.
-
(2003)
Cleve Clin J Med
, vol.70
, Issue.4
, pp. 361-371
-
-
Jaffer, A.1
Bragg, L.2
-
10
-
-
32644446621
-
The risk of hemorrhage among patients with warfarin-associated coagulopathy
-
Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol . 2006;47(4):804-808.
-
(2006)
J Am Coll Cardiol
, vol.47
, Issue.4
, pp. 804-808
-
-
Garcia, D.A.1
Regan, S.2
Crowther, M.3
Hylek, E.M.4
-
11
-
-
77953851760
-
Underuse of oral anticoagulants in atrial fibrillation: A systematic review
-
e634
-
Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med . 2010;123(7):638-645, e634.
-
(2010)
Am J Med
, vol.123
, Issue.7
, pp. 638-645
-
-
Ogilvie, I.M.1
Newton, N.2
Welner, S.A.3
Cowell, W.4
Lip, G.Y.5
-
12
-
-
65449163045
-
Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the united states
-
Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm . 2009;15(3):244-252.
-
(2009)
J Manag Care Pharm
, vol.15
, Issue.3
, pp. 244-252
-
-
Baker, W.L.1
Cios, D.A.2
Sander, S.D.3
Coleman, C.I.4
-
13
-
-
65649103773
-
Evaluating the impact of study-level factors on warfarin control in u.s.-based primary studies: A meta-analysis
-
Cios DA, Baker WL, Sander SD, Phung OJ, Coleman CI. Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis. Am J Health Syst Pharm . 2009;66(10):916-925.
-
(2009)
Am J Health Syst Pharm
, vol.66
, Issue.10
, pp. 916-925
-
-
Cios, D.A.1
Baker, W.L.2
Sander, S.D.3
Phung, O.J.4
Coleman, C.I.5
-
14
-
-
80052906902
-
Anticoagulation control in sweden: Reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry auricula
-
Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J . 2011;32(18):2282-2289.
-
(2011)
Eur Heart J
, vol.32
, Issue.18
, pp. 2282-2289
-
-
Wieloch, M.1
Sjalander, A.2
Frykman, V.3
Rosenqvist, M.4
Eriksson, N.5
Svensson, P.J.6
-
15
-
-
79953248796
-
2011 Accfahahrs focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the american college of cardiology foundation/american heart association task force on practice guidelines
-
Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm . 2011;8(1):157-176.
-
(2011)
Heart Rhythm
, vol.8
, Issue.1
, pp. 157-176
-
-
Wann, L.S.1
Curtis, A.B.2
January, C.T.3
-
16
-
-
0346992348
-
Direct thrombin inhibitors for anticoagulation
-
Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother . 2004;38(1):99-109.
-
(2004)
Ann Pharmacother
, vol.38
, Issue.1
, pp. 99-109
-
-
Nutescu, E.A.1
Wittkowsky, A.K.2
-
17
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med . 2009;361(12):1139-1151.
-
(2009)
N Engl J Med
, vol.361
, Issue.12
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
-
18
-
-
79953066921
-
2011 Accf/aha/hrs focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the american college of cardiology foundation/american heart association task force on practice guidelines
-
Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation . 2011;123(10):1144-1150.
-
(2011)
Circulation
, vol.123
, Issue.10
, pp. 1144-1150
-
-
Wann, L.S.1
Curtis, A.B.2
Ellenbogen, K.A.3
-
19
-
-
79952301326
-
Apixaban in patients with atrial fibrillation
-
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med . 2011;364(9):806-817.
-
(2011)
N Engl J Med
, vol.364
, Issue.9
, pp. 806-817
-
-
Connolly, S.J.1
Eikelboom, J.2
Joyner, C.3
-
20
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2011;365(11):981-992.
-
(2011)
N Engl J Med
, vol.365
, Issue.11
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
-
21
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med . 2011;365(10):883-891.
-
(2011)
N Engl J Med
, vol.365
, Issue.10
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
-
22
-
-
84877841791
-
-
Bayer Pharma AG. FDA approves Xarelto (rivaroxaban tablets) for the prophylaxis of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery Accessed January 6
-
Bayer Pharma AG. FDA approves Xarelto (rivaroxaban tablets) for the prophylaxis of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery. 2011. http://www.press. bayer.com/baynews/baynews.nsf/id/FDA-Approves-Xarelto-rivaroxaban-tablets- Prophylaxis-Deep-Vein-Thrombosis-Which-May-Lead-a-Pulmonary. Accessed January 6, 2012.
-
(2011)
, pp. 2012
-
-
-
23
-
-
45949095568
-
Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th edition
-
Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest . 2008;133(6)(suppl):546S-592S.
-
(2008)
Chest
, vol.133
, Issue.6 SUPPL.
-
-
Singer, D.E.1
Albers, G.W.2
Dalen, J.E.3
-
24
-
-
0037171819
-
Structure-based design of novel potent nonpeptide thrombin inhibitors
-
Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem . 2002;45(9):1757-1766.
-
(2002)
J Med Chem
, vol.45
, Issue.9
, pp. 1757-1766
-
-
Hauel, N.H.1
Nar, H.2
Priepke, H.3
Ries, U.4
Stassen, J.M.5
Wienen, W.6
-
25
-
-
55549147508
-
Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases
-
Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy . 2008;28(11):1354-1373.
-
(2008)
Pharmacotherapy
, vol.28
, Issue.11
, pp. 1354-1373
-
-
Baetz, B.E.1
Spinler, S.A.2
-
26
-
-
34548031359
-
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
-
Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol . 2007;64(3):292-303.
-
(2007)
Br J Clin Pharmacol
, vol.64
, Issue.3
, pp. 292-303
-
-
Stangier, J.1
Rathgen, K.2
Stahle, H.3
Gansser, D.4
Roth, W.5
-
27
-
-
84877851576
-
-
US Food and Drug Administration Clinical review for NDA 022-512 Pradaxa (dabigatran). Accessed January 6
-
US Food and Drug Administration. Clinical review for NDA 022-512 Pradaxa (dabigatran). http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugs AdvisoryCommittee/ucm226008.htm. Accessed January 6, 2012.
-
-
-
-
28
-
-
77953168824
-
Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
-
van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost . 2010;103(6):1116-1127.
-
(2010)
Thromb Haemost
, vol.103
, Issue.6
, pp. 1116-1127
-
-
Van Ryn, J.1
Stangier, J.2
Haertter, S.3
-
29
-
-
41949116970
-
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
-
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet . 2008;47(5):285-295.
-
(2008)
Clin Pharmacokinet
, vol.47
, Issue.5
, pp. 285-295
-
-
Stangier, J.1
-
30
-
-
0022997648
-
Clinical pharmacokinetics and pharmacodynamics of warfarin: Understanding the dose-effect relationship
-
Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet . 1986;11(6):483-504.
-
(1986)
Clin Pharmacokinet
, vol.11
, Issue.6
, pp. 483-504
-
-
Holford, N.H.1
-
31
-
-
59349098538
-
Coadministration of dabigatran etexilate and atorvastatin: Assessment of potential impact on pharmacokinetics and pharmacodynamics
-
Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs . 2009;9(1):59-68.
-
(2009)
Am J Cardiovasc Drugs
, vol.9
, Issue.1
, pp. 59-68
-
-
Stangier, J.1
Rathgen, K.2
Stahle, H.3
Reseski, K.4
Kornicke, T.5
Roth, W.6
-
32
-
-
84877859653
-
-
Pradaxa (dabigatran etexilate) [prescribing information]. Accessed January 6
-
Pradaxa (dabigatran etexilate) [prescribing information]. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.serdocBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed January 6, 2012.
-
(2012)
-
-
-
33
-
-
84877865472
-
-
Coumadin (warfarin) [prescribing information]. Accessed January 6
-
Coumadin (warfarin) [prescribing information]. http://www .accessdata.fda.gov/drugsatfda-docs/label/2010/009218s108lbl. pdf. Accessed January 6, 2012.
-
(2012)
-
-
-
34
-
-
19344366484
-
Systematic overview of warfarin and its drug and food interactions
-
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med . 2005;165(10):1095-1106.
-
(2005)
Arch Intern Med
, vol.165
, Issue.10
, pp. 1095-1106
-
-
Holbrook, A.M.1
Pereira, J.A.2
Labiris, R.3
-
35
-
-
38749131205
-
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
-
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos . 2008;36(2): 386-399.
-
(2008)
Drug Metab Dispos
, vol.36
, Issue.2
, pp. 386-399
-
-
Blech, S.1
Ebner, T.2
Ludwig-Schwellinger, E.3
Stangier, J.4
Roth, W.5
-
36
-
-
77956492689
-
The frequency of prescription of p-glycoprotein-affecting drugs in atrial fibrillation
-
Jungbauer L, Dobias C, Stollberger C, Weidinger F. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost . 2010;8(9):2069-2070.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.9
, pp. 2069-2070
-
-
Jungbauer, L.1
Dobias, C.2
Stollberger, C.3
Weidinger, F.4
-
37
-
-
84877849674
-
-
Pradaxa (dabigatran etexilate) [summary of product characteristics]. Accessed September 22
-
Pradaxa (dabigatran etexilate) [summary of product characteristics]. http://spaf.pradaxa.com/content/dam/internet/chc/pradaxa/com-COPY/documents/S mPC%20English%20version%20anx-104049-en-04Aug2011.pdf. Accessed September 22, 2011.
-
(2011)
-
-
-
38
-
-
84877871047
-
-
Pradax (dabigatran etexilate) [product monograph]. Accessed January 6
-
Pradax (dabigatran etexilate) [product monograph]. http://webprod3 .hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00013431. Accessed January 6, 2012.
-
(2012)
-
-
-
39
-
-
35348879239
-
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (petro study
-
Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol . 2007;100(9):1419-1426.
-
(2007)
Am J Cardiol
, vol.100
, Issue.9
, pp. 1419-1426
-
-
Ezekowitz, M.D.1
Reilly, P.A.2
Nehmiz, G.3
-
40
-
-
77952792359
-
Abstract 4629: Long-term open label extension of the prevention of embolic and thrombic events on dabigatran in atrial fibrillation (petro-ex study
-
Nagarakanti R, Ezekowitz MD, Parcham-Azad K, et al. Abstract 4629: long-term open label extension of the prevention of embolic and thrombic events on dabigatran in atrial fibrillation (PETRO-Ex study). Circulation . 2008;118:S-922.
-
(2008)
Circulation
, vol.118
-
-
Nagarakanti, R.1
Ezekowitz, M.D.2
Parcham-Azad, K.3
-
41
-
-
84877859360
-
-
US Food and Drug Administration. January 6
-
US Food and Drug Administration. Addendum to the clinical review for NDA 022-512 Pradaxa (dabigatran). http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM226012.pdf. January 6, 2012.
-
(2012)
Addendum to the Clinical Review for NDA 022-512 Pradaxa (dabigatran
-
-
-
42
-
-
78049490509
-
Newly identified events in the re-ly trial
-
Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med . 2010;363(19):1875-1876.
-
(2010)
N Engl J Med
, vol.363
, Issue.19
, pp. 1875-1876
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Reilly, P.A.4
Wallentin, L.5
-
43
-
-
77956977472
-
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the re-ly trial
-
Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet . 2010;376(9745):975-983.
-
(2010)
Lancet
, vol.376
, Issue.9745
, pp. 975-983
-
-
Wallentin, L.1
Yusuf, S.2
Ezekowitz, M.D.3
-
44
-
-
78650114177
-
Dabigatran and warfarin in vitamin k antagonist-naive and-experienced cohorts with atrial fibrillation
-
Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and-experienced cohorts with atrial fibrillation. Circulation . 2010;122(22):2246-2253.
-
(2010)
Circulation
, vol.122
, Issue.22
, pp. 2246-2253
-
-
Ezekowitz, M.D.1
Wallentin, L.2
Connolly, S.J.3
-
45
-
-
0028244264
-
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
-
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med . 1994;154(13):1449-1457.
-
(1994)
Arch Intern Med
, vol.154
, Issue.13
, pp. 1449-1457
-
-
-
46
-
-
0027505093
-
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
-
EAFT (European Atrial Fibrillation Trial) Study Group
-
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet . 1993;342(8882):1255-1262.
-
(1993)
Lancet
, vol.342
, Issue.8882
, pp. 1255-1262
-
-
-
47
-
-
78349313002
-
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the re-ly trial
-
Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol . 2010;9(12):1157-1163.
-
(2010)
Lancet Neurol
, vol.9
, Issue.12
, pp. 1157-1163
-
-
Diener, H.C.1
Connolly, S.J.2
Ezekowitz, M.D.3
-
48
-
-
77957699729
-
Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (esc
-
Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J . 2010;31(19):2369-2429.
-
(2010)
Eur Heart J
, vol.31
, Issue.19
, pp. 2369-2429
-
-
Camm, A.J.1
Kirchhof, P.2
Lip, G.Y.3
-
49
-
-
78751637313
-
Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion
-
Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation . 2011;123(2):131-136.
-
(2011)
Circulation
, vol.123
, Issue.2
, pp. 131-136
-
-
Nagarakanti, R.1
Ezekowitz, M.D.2
Oldgren, J.3
-
50
-
-
79953836474
-
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): A randomised, double-blind, noninferiority trial
-
Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, noninferiority trial. Thromb Haemost . 2010;105(4):721-729.
-
(2010)
Thromb Haemost
, vol.105
, Issue.4
, pp. 721-729
-
-
Eriksson, B.I.1
Dahl, O.E.2
Huo, M.H.3
-
51
-
-
35449007749
-
Oral dabigatran etexilate vs. Subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The re-model randomized trial
-
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost . 2007;5(11):2178-2185.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.11
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
-
52
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
-
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet . 2007;370(9591):949-956.
-
(2007)
Lancet
, vol.370
, Issue.9591
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
-
53
-
-
57649123692
-
Oral thrombin inhibitor dabigatran etexilate vs north american enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
-
Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty . 2009;24(1):1-9.
-
(2009)
J Arthroplasty
, vol.24
, Issue.1
, pp. 1-9
-
-
Ginsberg, J.S.1
Davidson, B.L.2
Comp, P.C.3
-
54
-
-
17444396697
-
Hepatic findings in long-term clinical trials of ximelagatran
-
Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf . 2005;28(4):351-370.
-
(2005)
Drug Saf
, vol.28
, Issue.4
, pp. 351-370
-
-
Lee, W.M.1
Larrey, D.2
Olsson, R.3
-
55
-
-
0642281257
-
Protocol for birmingham atrial fibrillation treatment of the aged study (bafta): A randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [isrctn89345269]
-
Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord . 2003;3:9.
-
(2003)
BMC Cardiovasc Disord
, vol.3
, pp. 9
-
-
Mant, J.W.1
Richards, S.H.2
Hobbs, F.D.3
-
56
-
-
0031967392
-
Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation
-
Marine JE, Goldhaber SZ. Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. Chest . 1998;113(4):1115-1118.
-
(1998)
Chest
, vol.113
, Issue.4
, pp. 1115-1118
-
-
Marine, J.E.1
Goldhaber, S.Z.2
-
57
-
-
0037817710
-
Anticoagulant-related bleeding in older persons with atrial fibrillation: Physicians' fears often unfounded
-
Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med . 2003;163(13):1580-1586.
-
(2003)
Arch Intern Med
, vol.163
, Issue.13
, pp. 1580-1586
-
-
Man-Son-Hing, M.1
Laupacis, A.2
-
58
-
-
79958126202
-
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (re-ly) trial
-
Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation . 2011;123(21):2363-2372.
-
(2011)
Circulation
, vol.123
, Issue.21
, pp. 2363-2372
-
-
Eikelboom, J.W.1
Wallentin, L.2
Connolly, S.J.3
-
59
-
-
79957715797
-
Anticoagulant options-Why the fda approved a higher but not a lower dose of dabigatran
-
Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med . 2011;364(19):1788-1790.
-
(2011)
N Engl J Med
, vol.364
, Issue.19
, pp. 1788-1790
-
-
Beasley, B.N.1
Unger, E.F.2
Temple, R.3
-
60
-
-
64349107688
-
Rationale and design of re-ly: Randomized evaluation of long-term anticoagulant therapy warfarin compared with dabigatran
-
e801-e802
-
Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J . 2009;157(5):805-810, e801-e802.
-
(2009)
Am Heart J
, vol.157
, Issue.5
, pp. 805-810
-
-
Ezekowitz, M.D.1
Connolly, S.2
Parekh, A.3
-
61
-
-
84877848345
-
-
US Food and Drug Administration Center For Drug Evaluation And Research Accessed January 6
-
US Food and Drug Administration, Center for Drug Evaluation and Research. Other reviews for NDA 022-512: dosing in subjects with renal failure. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022512Orig1s000OtherR. pdf. Accessed January 6, 2012.
-
(2012)
Other Reviews For NDA 022-512: Dosing In Subjects With Renal Failure
-
-
-
62
-
-
83055170914
-
Use of dabigatran etexilate in clinical practice: Confronting challenges to improve safety and effectiveness
-
Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nurescu EA. Use of dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy . 2011;31(12):1232-1249.
-
(2011)
Pharmacotherapy
, vol.31
, Issue.12
, pp. 1232-1249
-
-
Gulseth, M.P.1
Wittkowsky, A.K.2
Fanikos, J.3
Spinler, S.A.4
Dager, W.E.5
Nurescu, E.A.6
-
63
-
-
57449098437
-
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment
-
Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol . 2008;48(12):1411-1419.
-
(2008)
J Clin Pharmacol
, vol.48
, Issue.12
, pp. 1411-1419
-
-
Stangier, J.1
Stahle, H.2
Rathgen, K.3
Roth, W.4
Shakeri-Nejad, K.5
-
64
-
-
77952167209
-
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor
-
Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost . 2009;15(suppl 1):9S-16S.
-
(2009)
Clin Appl Thromb Hemost
, vol.15
, Issue.SUPPL. 1
-
-
Stangier, J.1
Clemens, A.2
-
65
-
-
77953158128
-
Measurement of the pharmacodynamic effect of dabigatran etexilate: Thrombin clotting time
-
abstract PP-TH-134
-
Stangier J, Wetzel K, Wienen W, van Ryn J, Rathgen K. Measurement of the pharmacodynamic effect of dabigatran etexilate: thrombin clotting time. J Thromb Haemost . 2009;7(suppl 2):abstract PP-TH-134.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.SUPPL. 2
-
-
Stangier, J.1
Wetzel, K.2
Wienen, W.3
Van Ryn, J.4
Rathgen, K.5
-
66
-
-
45949103309
-
Pharmacology and management of the vitamin k antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition
-
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest . 2008;133(6 suppl):160S-198S.
-
(2008)
Chest
, vol.133
, Issue.6 SUPPL.
-
-
Ansell, J.1
Hirsh, J.2
Hylek, E.3
Jacobson, A.4
Crowther, M.5
Palareti, G.6
-
67
-
-
80053571188
-
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects
-
[Epub ahead of print]
-
Erenberg ES, Kamphuisen PW, Sijpkens MK, Meijers HB, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation . 2011. [Epub ahead of print]
-
(2011)
Circulation
-
-
Erenberg, E.S.1
Kamphuisen, P.W.2
Sijpkens, M.K.3
Meijers, H.B.4
Buller, H.R.5
Levi, M.6
-
68
-
-
80052408267
-
Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models
-
van Ryn J, Litzenburger T, Waterman A, et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol . 2011;57(14):E1130.
-
(2011)
J Am Coll Cardiol
, vol.57
, Issue.14
-
-
Van Ryn, J.1
Litzenburger, T.2
Waterman, A.3
-
69
-
-
78649389908
-
Direct and indirect costs of management of long-term warfarin therapy in canada
-
Schulman S, Anderson DR, Bungard TJ, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost . 2010;8(10):2192-2200.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.10
, pp. 2192-2200
-
-
Schulman, S.1
Anderson, D.R.2
Bungard, T.J.3
-
70
-
-
77955677193
-
Hospitalization costs associated with warfarin-related bleeding events among older communitydwelling adults
-
Kim MM, Metlay J, Cohen A, et al. Hospitalization costs associated with warfarin-related bleeding events among older communitydwelling adults. Pharmacoepidemiol Drug Saf . 2010;19(7):731-736.
-
(2010)
Pharmacoepidemiol Drug Saf
, vol.19
, Issue.7
, pp. 731-736
-
-
Kim, M.M.1
Metlay, J.2
Cohen, A.3
-
71
-
-
84877864325
-
-
Red Book 2011. Red Book Online Edition Accessed January 6
-
Red Book 2011. Red Book Online Edition. Thomson Reuters, 2011. Accessed January 6, 2012.
-
(2012)
Thomson Reuters, 2011
-
-
-
72
-
-
79551589662
-
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
-
Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med . 2011;154(1):1-11.
-
(2011)
Ann Intern Med
, vol.154
, Issue.1
, pp. 1-11
-
-
Freeman, J.V.1
Zhu, R.P.2
Owens, D.K.3
-
73
-
-
79955774273
-
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A canadian payer perspective
-
Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost . 2011;105(5):908-919.
-
(2011)
Thromb Haemost
, vol.105
, Issue.5
, pp. 908-919
-
-
Sorensen, S.V.1
Kansal, A.R.2
Connolly, S.3
-
74
-
-
79958813704
-
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
-
Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation . 2011;123(22):2562-2570.
-
(2011)
Circulation
, vol.123
, Issue.22
, pp. 2562-2570
-
-
Shah, S.V.1
Gage, B.F.2
-
75
-
-
84877859991
-
-
Pradaxa (dabigatran etexilate mesylate) capsules gains preferred formulary status with AARP, nation's largest provider of Medicare Part D coverage. Ridgefield, CT (May 19, 2011). January 6
-
Pradaxa (dabigatran etexilate mesylate) capsules gains preferred formulary status with AARP, nation's largest provider of Medicare Part D coverage. Ridgefield, CT (May 19, 2011). http://www.thestreet. com/story/11125253/1/pradaxa-dabigatran-etexilate-mesylate-capsules-gains- preferred-formulary-status-with-aarp-nationslargest-provider-of-medicare-part-d- coverage.html. January 6, 2012
-
(2012)
-
-
-
76
-
-
84877847947
-
-
Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements. Accessed January 6
-
Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm249005.htm. Accessed January 6, 2012.
-
(2012)
-
-
-
77
-
-
84877854621
-
-
Pradaxa (dabigatran etexilate) [summary of product characteristics]. Accessed January 6
-
Pradaxa (dabigatran etexilate) [summary of product characteristics]. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf. Accessed January 6, 2012.
-
(2012)
-
-
-
78
-
-
84877863967
-
-
Accessed January 6, 432169 JCP XX X 10.1177/0091270011432169 Spinler
-
New drug application submitted to FDA for rivaroxaban for prevention of stroke in patients with atrial fibrillation. Johnson &Johnson, January 5, 2011. http://www.jnj.com/connect/news/all/new-drugapplication-submitted-to-fda- for-rivaroxaban-for-prevention-ofstroke-in-patients-with-atrial-fibrillation. Accessed January 6, 2012. 432169 JCP XX X 10.1177/0091270011432169 Spinler
-
(2012)
-
-
|